GLP-1 Agonist Treatment for Opioid Use Disorder - A Multi-Site Randomized Placebo-Controlled Trial

Go Back to All Clinical Trials

GLP-1 Agonist Treatment for Opioid Use Disorder - A Multi-Site Randomized Placebo-Controlled Trial

Brief description of study

The purpose of this research study is to determine whether once-weekly treatment with an investigational drug, semaglutide, may help reduce illicit opioid use compared to placebo in individuals with opioid use disorder who are receiving either buprenorphine or methadone.

Clinical Study Identifier: s24-01236

ClinicalTrials.gov Identifier: NCT06548490

Other Investigators: Jasdeep Mangat, Mathew B. Kladney.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies